Navigation Links
Kyowa Hakko’s Citicoline Obtains Novel Food Registration status in Europe

New York, NY (PRWEB) July 17, 2014

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) delivered a scientific opinion on Citicoline as a novel food ingredient (NFI), concluding on October 2013 that Citicoline is safe under the proposed uses and use levels.

Commission Implementing Decision 2014/423/EU of 1 July 2014 authorizing Kyowa Hakko the placing on the market of Citicoline as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council. ( )

Citicoline is intended to be used in food supplements in Europe aimed at adult population at a maximum level of 500 mg/day, and in foods for particular nutritional uses, specifically foods for special medical purposes, at a maximum level of 250 mg/serving, and with a maximum daily intake from these types of foods of 1,000 mg/day.

Citicoline is the generic name for CDP-choline (choline cytidine 5’-pyrophosphate), organic molecule produced endogenously and found in all living cells. Is a source of choline and precursor for the synthesis of phospholipids that are essential constituents of cell membranes, including phosphatidylcholine, phosphatidylserine and phosphatidyl-ethanolamine.

In United States, under Cognizin® brand name, Kyowa Hakko USA, Inc. has been marketing Citicoline since the early 1980’s as dietary supplement and created the trademark name in 2004, received self-affirmed Generally Recognized As Safe (GRAS) status in 2009, as food ingredient for use at levels of 250 mg per serving in such products as dietary supplements, beverages, breakfast cereals, chewing gum, pastas, hard candies, milk products, fruit juices and soft candy.

Cognizin® Citicoline is often called a “brain nutrient” because it increases levels of several important neurotransmitters including acetylcholine, dopamine and noradrenaline; helps maintain the integrity of neuronal cell membranes and increases energy production in the frontal cortex.

About Cognizin® Citicoline
A proprietary form of Citicoline, Cognizin® is a potent brain-health nutrient that’s been clinically studied to support mental energy, focus, attention and recall. Tested in human clinical trials and developed using a patented fermentation process, Cognizin® is a pure, allergen-free GRAS ingredient that’s stable and effective.
For more information on Cognizin®, go to

About Kyowa Hakko Europe
Kyowa Hakko Europe and Kyowa Hakko Bio Italia are the Central-North and South European sales office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. For more information visit or email at finechemicals(at)kyowa(dot)it

About Kyowa Hakko USA
Kyowa Hakko USA is the North American sales office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as Sustamine® L-Alanyl-L-Glutamine. For more information visit

# # #

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Citicoline Supplement Doesnt Help Treat Brain Injury, Study Finds
2. Petra Beli joins IMB, obtains Emmy Noether award to study cellular response to DNA damage
3. Mainz University obtains new CRC Nanodimensional polymer therapeutics for tumor therapy
4. Albertson & Davidson, LLP Obtains Court Order Requiring California Trustee to Provide Pre-Death Accounting
5. Tanimura & Antle Artisan® Lettuce Obtains American Heart Association Heart-Check Food Certification
6. Car Accident Victim Obtains $1.9 Million Settlement from Insurance Company, Says Washington D.C. Personal Injury Attorney Mike Slocumb
7. NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection
8. NUS researchers discover novel protein complex with potential to combat gastric cancer
9. New possibilities for leukemia therapy with a novel mode of leukemia cell recognition
10. Molecular imaging finds novel way to knock down breast cancer
11. Researchers at the Gladstone Institutes find novel approach to reactivate latent HIV
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology: